Clinical Trial Update: The Utility of Ischemia Modified Albumin (IMA) in Sepsis

View source ↗

Summary

A completed clinical trial evaluating ischemia-modified albumin as a biomarker for sepsis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sepsis
• Sepsis Syndrome
• Systemic Inflammatory Response Syndrome

Snippet

Sponsor: Inverness Medical Innovations | Conditions: Sepsis, Severe Sepsis | Status: COMPLETED